周戈耀,田海玉,陈文佼,常悦,李端,禄晓龙,孟小夏,胡嘉琦,樊兴颖
ZHOU Geyao,TIAN Haiyu,CHEN Wenjiao,CHANG Yue,LI Duan,LU Xiaolong,MENG Xiaoxia,HU Jiaqi,FAN Xingying

• 1:贵州医科大学

摘要(Abstract)：

目的:初步构建基于大健康的医药产业发展能力评价指标体系,为分析医药产业的可持续发展能力提供依据。方法:以医药产业的中药民族药产业、小分子化学药产业、生物制品产业、医疗器械产业及医药衍生品产业的5个子产业为研究对象,通过查阅文献结合召开专题小组讨论会的方式确定各子产业指标体系的纳入指标及参考权重,并采用调查方式对构建的指标体系进行测评,评价其合理性和可行性。结果:医药产业的5个子产业构建的指标体系为树形结构,包括一级指标和二级指标;各子产业指标体系6个一级指标相同,分别是资源投入回报能力、研究开发能力、生产制造能力、市场营销能力、组织管理能力及社会效益能力;参考权重为资源投入回报能力最高,其次为研究开发能力,社会效益能力最低;而纳入的二级指标不同,包括定量指标参考权重为资源投入回报能力最高,其次为研究开发能力,社会效益能力最低定性指标,二级指标的参考权重不同;经实测,各指标体系评价结果与客观事实相符合的比率均为100%,提示所建立的指标体系具有合理性和可行性。结论:初步构建的指标体系所纳入指标及参考权重符合医药产业发展趋势、特点。
Objective: To investigate the construction of the evaluation index system of the development ability of pharmaceutical industry based on Big Health,and to provide the reference for analyzing and evaluating the sustainable development ability of pharmaceutical industry. Methods: Taking Ethonmedicine industry,small molecular chemical industry,biological products industry,medical equipment industry and medical derivatives industry as research subjects,combined with literature review and seminar discussion to determine targeting indexs and reference weight of each subindustry index system,the rationality and feasibility of the index system. Results: All constructed index systems are tree structure,including primary and secondary indexes. Six primary indexes of each subindustry's index system are the same. They are return on investment,research and development,manufacturing capability,marketing,organizing and administration and social benefits. Reference weight placed return on investment as the highest one,reserch and development as secondary and social benefits as the lowest. Secondary indexes are different,quantitative indexes reference weight showed return on investment as the highest,research development as secondadry,social benefits as the lowest qualitative inde-xes. It was tested that the ratio of the evaluation results of each index system to the objective fact was100%,which proved the rationality and feasibility of such system. Conclusions: Indexes and reference weight concluded in index systems conform to the development trend and characteristics of pharmaceutical industry.

关键词(KeyWords)： 大数据;大健康;医药产业;发展能力;评价;指标体系
big data;big Health;pharmaceutical industry;development ability;evaluation;index system

Abstract:

Keywords:

基金项目(Foundation): 贵州省科技厅软科学项目[黔科合基础(2016)1515-1]

作者(Author): 周戈耀,田海玉,陈文佼,常悦,李端,禄晓龙,孟小夏,胡嘉琦,樊兴颖
ZHOU Geyao,TIAN Haiyu,CHEN Wenjiao,CHANG Yue,LI Duan,LU Xiaolong,MENG Xiaoxia,HU Jiaqi,FAN Xingying

DOI: 10.19367/j.cnki.1000-2707.2017.06.010

参考文献(References)：

• [1]贵州省人民政府.省人民政府印发《贵州省关于加快推进新医药产业发展的指导意见》、《贵州省新医药产业发展规划(2014—2017年)》的通知[EB/OL].(2014-08-03)[2015-09-02]http://www.gzgov.gov.cn/xxgk/zfxxgkpt/szfxxgkml/201507/t20150703_304180.html.
• [2]何燕.企业发展能力分析与评价[D].西安:西安建筑科技大学,2004
• [3]李玉辉.企业可持续发展评价[J].大庆石油学院学报,2007(3):56-62.
• [4]权锡鉴.企业可持续发展能力研究[D].青岛:中国海洋大学,2005
• [5]崔国瑞.高新技术企业综合发展能力评价研究[D].成都:四川大学,2003.
• [6]周戈耀,朱昌蕙,常悦,等.中药生产企业自主创新能力评价指标体系研究[J].中国药房,2011(31):2881-2883.
• [7]孙世光,石亚飞,王苏会,等.应用德尔菲法构建中药注射剂安全性评价指标体系[J].中国药房,2015(6):729-731.
• [8]石亚飞,闫荟,王苏会,等.德尔菲法构建中药注射剂研发阶段安全性评价指标体系[J].中国医院药学杂志,2013(24):2074-2075.
• [9]任小巧,倪健,杜守颖,等.贵州中药产业发展现状及战略思考[J].中国中医药信息杂志,2014(2):1-4.
• [10]丁健.中国药物创新的机遇与展望——在“科学监管通化交流峰会”上的报告[J].中国食品药品监管,2011(10):10-13.

文章评论(Comment)：